profit from every $100 of sales.
$0$100
Sanara MedTech
$32.35-0.58% today
+65.0% in 1 year
1-year low $16.341-year high $35.28
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Sanara MedTech sold, what it kept, and what it did with the cash.
Sales went from $45.8 million in 2022 to $103 million in 2025, with -$37.6 million of profit last year.
SalesProfit
Sanara MedTech vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Sanara MedTech | No profit yet | ||
 ResMed | 22.1× · Fair price | ||
 West Pharmaceutical Services | 58.8× · Expensive | ||
 Hologic | 30.0× · Fair price | ||
 Baxter International | No profit yet |
AI analysis
An AI analyst reads Sanara MedTech's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 46 | 65 | 87 | 103 | |
| 39 | 57 | 79 | 96 | |
| -12 | -8 | 1 | 9 | |
| -12 | -0 | 6 | 10 | |
| -8 | -4 | -10 | -38 | |
| -1.00 | -0.52 | -1.14 | -4.36 | |
| 86.1% | 87.9% | 90.6% | 92.7% | |
| -26.7% | -11.8% | 1.4% | 8.9% | |
| -17.3% | -6.6% | -11.2% | -36.4% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 61 | 74 | 88 | 73 |
| Cash | 9 | 5 | 16 | 17 |
| Total debt | 1 | 12 | 32 | 48 |
| Total liabilities | 19 | 29 | 49 | 67 |
| 42 | 45 | 39 | 6 | |
| 8 | 8 | 8 | 9 | |
| -25.8% | -5.5% | 1.3% | 9.3% | |
| -19.0% | -9.6% | -24.5% | -632.5% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -6 | -3 | -0 | 7 | |
| 1 | 0 | 0 | 5 | |
| -6 | -4 | -0 | 2 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 3 | 3 | 4 | 5 |
Valuation
- –
- 281.3×
- –
- 26.1×
- 2.9×
- 139.0×
- 31.9×
- 0.7%
- -12.6%
- 0.0%
Profitability
- 92.7%
- 8.9%
- -36.4%
- 10.6%
- 15.1%
- -26.9%
- -246.4%
- -48.5%
- 15.2%
- 4.7%
Growth
- +31.0%
- –
- +953.9%
- –
- +4.1%
Financial health
- 3.0×
- 6.88
- 69.8%
- 1.2×
- 2.28
- 2.05
- 1.55
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Top 15%of 963
Bottom 46%of 894
Top 18%of 908
Bottom 43%of 991
What analysts expect
- Average price target
- $32.00
- Range
- $32.00 – $32.00
- 1 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 11, 2026 | 0.04 | -0.04 | +200.0% |
| Mar 24, 2026 | 0.04 | 0.11 | −63.6% |
| Nov 12, 2025 | 0.09 | -0.24 | +137.5% |
| Aug 13, 2025 | -0.23 | -0.33 | +30.3% |
| May 14, 2025 | -0.41 | -0.31 | −32.3% |
| Mar 25, 2025 | -0.18 | -0.19 | +5.3% |
| Nov 12, 2024 | -0.34 | -0.62 | +45.2% |
| Aug 12, 2024 | -0.41 | -0.21 | −95.2% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
21No pass
Benjamin Graham
16No pass
Philip Fisher
44No pass
Peter Lynch
45No pass
Joel Greenblatt
11No pass
Charlie Munger
24No pass
Terry Smith
28No pass
Questions about Sanara MedTech
Is Sanara MedTech a good stock to buy?
A business with weak numbers that is not profitable yet. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Sanara MedTech AI analysis
What does Sanara MedTech do?
Sanara MedTech Inc. develops, markets, and distributes wound and skin care products to physicians, hospitals, clinics, and post-acute care settings in the United States. It is in Medical - Instruments & Supplies.
Does Sanara MedTech pay a dividend?
No. Sanara MedTech does not pay a dividend at the moment.
Is Sanara MedTech stock halal?
Yes. Sanara MedTech passes our halal screen: its business is permitted and its debt is 16% of its market value, under the 30% limit. How we check
How has Sanara MedTech stock done over the past year?
Up 65.0% over the past twelve months, to $32.35. It traded between $16.34 and $35.28 and is 8.3% below its high.
Who are Sanara MedTech's competitors?
The largest listed companies in the same industry are ResMed, West Pharmaceutical Services, Hologic and Baxter International. The peers table on this page compares their profit, growth and price with Sanara MedTech's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.